Abstract

In fiscal year 2009, we published the data on hand-foot skin reaction related to sorafenib therapy from three NCI intramural trials to better understand the potential risk factors and possible pathogenesis of this painful treatment-limiting cutaneous adverse effect. This research required multi-specialty collaboration among dermatologists, oncologists, pharmacologists and statisticians. Patients on other investigational therapeutics are being systematically evaluated dermatologically at baseline and while on treatment. In addition to thorough clinical evaluations, subjects may undergo skin biopsies and medical photography.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010940-02
Application #
7965853
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2009
Total Cost
$42,092
Indirect Cost

  Institution

Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

O'Sullivan Coyne, Geraldine; Woodring, Therese S; Lee, Chyi-Chia R et al. (2018) Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase. J Invest Dermatol 138:979-981
Pichard, Dominique C; Cardones, Adela R; Chu, Emily Y et al. (2016) Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatol 152:227-8
Brooks, Sara; Linehan, W Marston; Srinivasan, Ramaprasad et al. (2011) Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol 147:364-5
Jain, Lokesh; Gardner, Erin R; Figg, William D et al. (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30:52-6
Azad, Nilofer S; Aragon-Ching, Jeanny B; Kong, Heidi H (2009) Clin Cancer Res 15:7749
Azad, Nilofer S; Aragon-Ching, Jeanny B; Dahut, William L et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-6
Kong, Heidi H; Turner, Maria L (2009) Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 61:360-1
Kong, Heidi H; Fine, Howard A; Stern, Jere B et al. (2009) Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 145:923-5
Lacouture, Mario E; Wu, Shenhong; Robert, Caroline et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-11
Kong, Heidi H; Sibaud, Vincent; Chanco Turner, Maria L et al. (2008) Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 144:820-2